Erasca, Inc. (ERAS) stock
ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.76−0.13 (-0.94%)
Close on Nov 18, 2026Market cap $4.81BP/E –Yield 0.00%
Erasca operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Erasca's operating cash flow for the twelve months ending Jun 30, 2026 was -$98.02M. For fiscal 2025 it was -$95.46M. The highest annual figure on record is -$32.69M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$95.46M | – |
| FY2024 | Dec 31, 2024 | -$109.42M | – |
| FY2023 | Dec 31, 2023 | -$101.22M | – |
| FY2022 | Dec 31, 2022 | -$103.26M | – |
| FY2021 | Dec 31, 2021 | -$79.60M | – |
| FY2020 | Dec 31, 2020 | -$32.69M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$27.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.66M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.14M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.22M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.48M | – |
See a number that looks wrong?